MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
8 hedge funds and large institutions have $141K invested in MABVAX THERAPEUTICS HLDGS INC in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less capital invested
Capital invested by funds: $281K → $141K (-$140K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.3K |
| 2 |
SBL
Sargent Bickham Lagudis
Boulder,
Colorado
|
+$9 |
| 3 |
Wells Fargo
San Francisco,
California
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$53K |
| 2 |
Millennium Management
New York
|
-$29.8K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$738 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
Biomark Capital Management
Greenwich,
Connecticut
| $61K | – | – | – |
|
|
2
Millennium Management
New York
| $46K | -$29.8K | -3,438 | -34% |
|
|
DRD
3
Dennis R. Delaney
| $23K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $11K | +$14.3K | +1,652 | New |
|
|
VKH
5
Virtu KCG Holdings
New York
| – | -$53K | -5,264 | Closed |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$738 | -85 | -99% |
|
|
SBL
7
Sargent Bickham Lagudis
Boulder,
Colorado
| – | +$9 | +1 | New |
|
|
8
Wells Fargo
San Francisco,
California
| – | +$9 | +1 | New |
|
MBVX Hedge Fund Activity: Q1 2017 in Review
8 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q1 2017, worth a combined $141K — down 50% from $281K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MBVX positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $14.3K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $53K sold.
- 8 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q1 2017, up from 7 in Q4 2016.
- Funds reported $141K of MABVAX THERAPEUTICS HLDGS INC stock for Q1 2017, down 50% quarter-over-quarter.
- 3 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q1 2017 and 2 closed out, a net change of +1 holder.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q1 2017 was UBS Group, an estimated $14.3K added.
- The largest MABVAX THERAPEUTICS HLDGS INC seller in Q1 2017 was Virtu KCG Holdings, an estimated $53K sold.
Based on aggregated 13F filings for Q1 2017.